TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A paper in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems involving the whole motor system, including the brain, nerves and muscle. The authors propose changes to research and clinical assessment, but say the suggested measures have not yet been shown to improve outcomes or lower costs.
Researchers writing in The Lancet Healthy Longevity argue that weakness and mobility loss in older adults should not be treated as muscle problems alone: age-related changes across the brain, spinal cord, nerves and their connections to muscle may also impair movement. Their proposed reframing could influence how sarcopenia is studied and assessed, although the authors say the suggested clinical measures still need validation.
The paper, by Lucas B. R. Orssatto and colleagues, says muscle loss explains only a modest part of the decline in strength observed with age. People with similar amounts of muscle can have very different strength and mobility, the authors note. They argue that the systems that plan and control movement can also become less effective, weakening the signals that activate muscles and affecting balance and the sense of body position.
The authors point to a change already made in how sarcopenia is assessed: grip strength, walking speed and chair-stand performance are used because they predict outcomes such as falls and disability better than muscle mass alone. But, they argue, the explanation of sarcopenia has not caught up with those functional measures and remains centered on muscle.
The article calls for diagnostic working groups to consider a five-point research and assessment agenda. In primary care, the authors suggest observing how quickly someone rises from a chair, whether they become unsteady during sustained effort, hand dexterity and walking while carrying out another task, such as talking. They also recommend closer examination when weakness is asymmetric, develops rapidly or appears disproportionate to muscle loss. These are proposals, not established replacements for current screening.
Falls and Independence at Stake
The question matters because declining strength and movement can make routine tasks harder and raise the risk of falls, disability and loss of independence. The Medical Xpress report says sarcopenia affects up to 29% of older adults living in the community, with higher rates in hospitals and residential care and among people with multiple health conditions or frailty.
Australian figures in the report illustrate the potential public-health consequences of falls: 253,800 fall-related hospitalizations in 2024–25, and 6,722 deaths following a fall in the preceding year. The reported estimate for health-system costs from fall injuries was A$5.4 billion. These figures describe falls and their burden; they do not show that the proposed motor-system approach would prevent them.
If the authors’ framing is supported by further research, it could direct clinicians and researchers to consider more than muscle-building when addressing impaired function. The paper argues for research and care that measure movement and strength, and examine the nervous system’s role, rather than relying mainly on whether muscle mass increases.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
From Muscle Mass to Movement
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. The report describes it as a contributor to frailty and disability, while noting that falls are a major consequence of reduced mobility. In recent years, diagnostic assessment has put more weight on what people can do—such as grip, walking and standing from a chair—than on muscle size alone.
The paper’s central argument is that this functional approach has not been matched by a broader account of what causes weakness. The authors say that muscle mass and everyday ability do not always move together. They also note that power can decline earlier and faster than muscle mass, and that getting up from a chair depends on rapid coordination and nerve recruitment as well as muscle bulk.
The report also describes recent Australian primary-care guidance: earlier in 2026, the Australian Journal of General Practice published a proposed algorithm for screening, assessment and management of poor muscle health. The Lancet Healthy Longevity paper builds on that discussion by asking whether assessment should account more explicitly for the wider motor system.
“Nobody has yet shown that these measures beat existing screens, either on outcomes or on cost.”
— The authors, as reported by Medical Xpress
Clinical Tests Still Need Validation
The paper presents a reframing and research agenda, not proof that motor-system assessments are better than current screening. The authors say it has not been shown that the suggested observations improve patient outcomes or reduce costs compared with existing measures. It is also unclear which practical tests would work reliably across primary-care settings.
The availability of clinicians with neuromuscular expertise varies, according to the report, which may affect how readily a broader assessment could be adopted. The source does not establish that particular medicines, exercise programs or other interventions will prevent falls by addressing the proposed motor-system changes. The scale of any effect on diagnosis, treatment or independence remains unknown.
Evidence Needed Before Practice Changes
The authors call for investment in practical tests that can be validated, guidelines that support a staged assessment and clinical trials that measure nerve function as well as muscle. Those steps could help determine whether the proposed approach identifies meaningful differences between patients and whether it leads to better function or fewer adverse outcomes.
For now, the paper does not announce a change to diagnostic criteria or establish a new standard of care. The next milestones are evidence from validation studies and trials, followed by consideration by the international working groups responsible for sarcopenia criteria. Until that evidence is available, the authors’ recommendations remain proposals for research and clinical discussion.
Key Questions
What is the paper proposing about sarcopenia?
It argues that sarcopenia should be understood as a condition involving the aging motor system, including the brain, spinal cord, nerves and muscle, rather than muscle alone.
Does the paper show that muscle loss is not involved?
No. The authors do not say muscle is irrelevant. They argue that muscle loss explains only a modest part of strength decline and that other parts of the movement-control system may also contribute.
What changes to assessment do the authors suggest?
They suggest observing measures such as chair-rise speed, steadiness, hand dexterity and walking while talking, alongside existing measures. These suggestions have not yet been shown to outperform current screening.
Has the proposed approach been shown to prevent falls?
No. The report does not show that the suggested assessment or the broader motor-system framing prevents falls. The authors say outcome and cost benefits have not yet been established.
What evidence is needed next?
The authors call for studies validating practical tests, updated guidance and trials that measure nerve function as well as muscle and assess outcomes relevant to everyday movement.
Source: medicalxpress.com
